Iovance Biotherapeutics (IOVA) Stock Forecast & Price Target

$6.40

-0.33 (-4.90%)

(As of 12/8/2023 ET)

Today's Range: $6.33
▼
$6.83
50-Day Range: $3.30
▼
$6.73
52-Week Range: $3.21
▼
$9.36

Volume: 7.21 million shs
Average Volume: 6.72 million shs
Market Capitalization: $1.64 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $20.33

Iovance Biotherapeutics Consensus Analyst Rating and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Analysts' Consensus Rating

Buy
Based on 11 Analyst Ratings

Analysts' Consensus Price Target

$20.33
217.71% Upside

High Forecast	$30.00
Average Forecast	$20.33
Low Forecast	$12.00

Type	Current Forecast 12/10/22 to 12/10/23	1 Month Ago 11/10/22 to 11/10/23	3 Months Ago 9/11/22 to 9/11/23	1 Year Ago 12/10/21 to 12/10/22
Consensus Rating	Buy	Moderate Buy	Moderate Buy	Moderate Buy
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	11 Buy rating(s)	10 Buy rating(s)	7 Buy rating(s)	6 Buy rating(s)
Hold	0 Hold rating(s)	2 Hold rating(s)	3 Hold rating(s)	5 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$20.33	$18.77	$18.55	$19.82
Predicted Upside	217.71% Upside	194.59% Upside	155.61% Upside	118.73% Upside

Get Iovance Biotherapeutics Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for IOVA and its competitors with MarketBeat's FREE daily newsletter.

IOVA Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

IOVA Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Iovance Biotherapeutics Stock vs. The Competition

Type	Iovance Biotherapeutics	Medical Companies	S&P 500
Consensus Rating Score	2.92	2.68	2.49
Consensus Rating	Moderate Buy	Moderate Buy	Hold
Predicted Upside	200.48% Upside	737.05% Upside	3,819.11% Upside
News Sentiment Rating	Neutral News	Positive News	Positive News

Recent Analyst Ratings and Stock Forecasts

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Action	Rating	Price Target	Upside/Downside on Report Date
11/20/2023	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$12.00	+137.62%
11/7/2023	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Buy ➝ Buy	$38.00 ➝ $28.00	+548.15%
9/18/2023	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Overweight ➝ Overweight	$40.00 ➝ $18.00	+241.56%
9/15/2023	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$18.00	+223.16%
9/15/2023	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$30.00	+445.45%
9/15/2023	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$17.00	+209.09%
9/13/2023	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Buy ➝ Buy	$27.00 ➝ $26.00	+342.93%
8/16/2023	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$29.00	+309.03%
8/9/2023	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target		$23.00 ➝ $20.00	+180.11%
5/30/2023	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Equal Weight ➝ Overweight	$11.00 ➝ $17.00	+105.07%
3/1/2023	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Outperform	$25.00 ➝ $15.00	+105.76%
1/27/2023	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Overweight	$11.00 ➝ $14.00	+82.05%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Sunday at 01:37 AM ET.

IOVA Price Target - Frequently Asked Questions

What is Iovance Biotherapeutics's consensus rating and price target?: According to the issued ratings of 11 analysts in the last year, the consensus rating for Iovance Biotherapeutics stock is Buy based on the current 11 buy ratings for IOVA. The average twelve-month price prediction for Iovance Biotherapeutics is $20.33 with a high price target of $30.00 and a low price target of $12.00. Learn more on IOVA's analyst rating history.
Do Wall Street analysts like Iovance Biotherapeutics more than its competitors?: Analysts like Iovance Biotherapeutics more than other Medical companies. The consensus rating for Iovance Biotherapeutics is Buy while the average consensus rating for medical companies is Moderate Buy. Learn more on how IOVA compares to other companies.
Does Iovance Biotherapeutics's stock price have much upside?: According to analysts, Iovance Biotherapeutics's stock has a predicted upside of 229.30% based on their 12-month stock forecasts.

What analysts cover Iovance Biotherapeutics?: Iovance Biotherapeutics has been rated by Barclays, HC Wainwright, JMP Securities, Mizuho, Stifel Nicolaus, The Goldman Sachs Group, and Truist Financial in the past 90 days.

Stock Ratings Reports and Tools

Related Companies:

Today's Ratings:

Top Rated Stocks:

More Ratings Tools:

This page (NASDAQ:IOVA) was last updated on 12/10/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial